Secondary hyperparathyroidism (SHPT) is characterized by elevated levels of parathyroid hormone (PTH), parathyroid hyperplasia, calcium and phosphorus metabolism disorders, as well as clinical conditions such as renal bone disease and vascular calcification. This evidence concerns the gene PTH and metabolic disease.